Technology
Health
Biotechnology

VistaGen Therapeutics

$0.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0145 (2.93%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell VTGN and other stocks, options, ETFs, and crypto commission-free!

About VTGN

VistaGen Therapeutics, Inc. Common Stock, also called VistaGen Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Read More Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Employees
9
Headquarters
South San Francisco, California
Founded
1998
Market Cap
21.74M
Price-Earnings Ratio
Dividend Yield
Average Volume
222.92K
High Today
$0.53
Low Today
$0.498
Open Price
$0.498
Volume
190.63K
52 Week High
$2.44
52 Week Low
$0.3801

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Pharmaceutical
US

VTGN Earnings

-$0.42
-$0.31
-$0.20
-$0.09
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
Actual
Available Aug 13, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.